4.4 Article

Comparing paclitaxel-platinum with ifosfamide-platinum as the front-line chemotherapy for patients with advanced-stage uterine carcinosarcoma

Related references

Note: Only part of the references are listed.
Editorial Material Medicine, General & Internal

Does the combination of hysterectomy and general anesthesia increase the risk of subsequent development of dementia?

Wen-Ling Lee et al.

JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2021)

Editorial Material Medicine, General & Internal

The predictors of sepsis-related acute kidney injury

Wen-Ling Lee et al.

JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2021)

Letter Medicine, General & Internal

Can the simple parameter of peripheral hematological examination predict the outcome in patients with septic acute kidney injury?

Fa-Kung Lee et al.

JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2021)

Editorial Material Medicine, General & Internal

Application of hyaluronic acid in patients with interstitial cystitis

Wen-Ling Lee et al.

JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2021)

Review Oncology

Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity

Shinya Matsuzaki et al.

Summary: Uterine carcinosarcoma is an aggressive high-grade endometrial cancer with increasing incidence. Multimodal treatment is the mainstay, but survival outcomes remain dismal.

GYNECOLOGIC ONCOLOGY (2021)

Article Oncology

Immunogenomic landscape of gynecologic carcinosarcoma

Osamu Gotoh et al.

Summary: The study investigated the influence of immune cells infiltrating carcinosarcoma of the uterus or ovary to better understand the immunological status of gynecological CS. Different molecular subtypes of CS exhibited distinct tumor immune microenvironments and patient outcomes, highlighting the potential clinical utility of tumor immune microenvironmental analyses above genomic aberration subtype classification.

GYNECOLOGIC ONCOLOGY (2021)

Article Oncology

A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis

Mitsuya Ishikawa et al.

Summary: This study aimed to assess the efficacy and safety of dose-dense weekly paclitaxel plus carboplatin with or without bevacizumab compared to conventional, tri-weekly paclitaxel plus carboplatin with or without bevacizumab in metastatic or recurrent cervical carcinoma. The study did not meet its primary endpoint, indicating that the dose-dense regimen may not be promising for this type of cancer.

GYNECOLOGIC ONCOLOGY (2021)

Article Obstetrics & Gynecology

Effect of adjuvant therapy on the prognosis in stage I/II uterine carcinosarcoma: A meta-analysis

Fei Zhao et al.

Summary: Chemotherapy and radiochemotherapy are associated with improved progression-free survival and 5-year overall survival in early-stage uterine carcinosarcoma patients, while radiotherapy alone shows no statistical significance in this aspect.

JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (2021)

Editorial Material Medicine, General & Internal

Is one-minute difference in operation time meaningful?

Wen-Hsun Chang et al.

JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2021)

Article Medicine, General & Internal

Adjuvant therapy and prognosis in uterine carcinosarcoma

Chi-Yuan Chiang et al.

Summary: The study aimed to investigate prognostic factors and the impact of adjuvant treatment in uterine carcinosarcoma (UCS) patients. Adjuvant chemoradiation was confirmed as an independent good prognostic factor, while older age, advanced stage, and adnexal metastasis were associated with poor outcomes in UCS. Further analysis revealed significant improvement in outcomes with adjuvant chemoradiation compared to adjuvant chemotherapy in specific patient groups.

JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2021)

Review Oncology

Uterine carcinosarcoma: An overview

Gaetano Pezzicoli et al.

Summary: Uterine carcinosarcoma, also known as malignant mixed M & uuml;llerian tumor, is a rare gynecological malignancy with poor prognosis. Surgical resection is the best curative option for localized disease, and additional peri-operative treatments have been shown to improve outcomes. Palliative chemotherapy is the treatment of choice for metastatic disease, with no consensus on the best regimen.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)

Article Oncology

Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis

Sarah A. Ackroyd et al.

Summary: In the Markov model, first-line therapy with P/L for advanced or recurrent endometrial cancer was found to increase costs and worsen outcomes in the MSS cohort, while it improved survival and QALYs in the MSI-high cohort but was not cost-effective at the current drug cost.

GYNECOLOGIC ONCOLOGY (2021)

Review Oncology

Uterine carcinosarcomas: From pathology to practice

Michael D. Toboni et al.

Summary: The review summarized the latest research and clinical trial data on uterine carcinosarcoma, highlighting the lack of evidence for early-stage disease treatment and the valuable information provided by recent results from GOG 261 for treatment strategies, indicating potential use of more targeted agents for UCS in the future.

GYNECOLOGIC ONCOLOGY (2021)

Editorial Material Medicine, General & Internal

Is the lower serum level of vitamin E associated with pregnant women with allergic rhinitis?

Yiu-Tai Li et al.

JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2021)

Editorial Material Obstetrics & Gynecology

Growth differentiation factor 15 in pregnant women: A hero or villain?

Yiu-Tai Li et al.

TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY (2021)

Article Obstetrics & Gynecology

Adjuvant Treatment Modalities, Prognostic Factors, and Outcome of the Uterine Carcinosarcoma

Ilker Kahramanoglu et al.

Summary: The study found that sarcoma dominance in UCS patients is associated with poor survival, while adjuvant therapy did not affect recurrence or survival. Continuous monitoring and more effective postoperative strategies are needed to improve patient outcomes.

JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA (2021)

Review Oncology

Adjuvant vaginal interventional radiotherapy in early-stage non-endometrioid carcinoma of corpus uteri: a systematic review

Francesca De Felice et al.

Summary: This systematic review focused on rare histological types of corpus uteri malignancy, including uterine carcinosarcoma (UCS), uterine clear cell carcinoma (UCCC), and uterine papillary serous carcinoma (UPSC), and the role of vaginal interventional radiotherapy (VIRt) was investigated in their managements. The results suggest that VIRt alone may be suitable in adequately selected early-stage UPSC and UCCC patients, while a multidisciplinary therapeutic approach is needed for early-stage UCS patients.

JOURNAL OF CONTEMPORARY BRACHYTHERAPY (2021)

Article Medicine, General & Internal

Evaluation of treatment results and prognostic factors of uterine sarcoma: A single-center experience

Mozhdeh Momtahan et al.

JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2020)

Review Oncology

Adjuvant chemotherapy in endometrial cancer

Cesar Gomez-Raposo et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)

Review Medicine, General & Internal

Aberrant sialylation in ovarian cancers

Wen-Ling Lee et al.

JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2020)

Editorial Material Medicine, General & Internal

Uterine sarcoma: An unusual but high lethal disease of gynecological malignancies

Wen-Ling Lee et al.

JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2020)

Article Obstetrics & Gynecology

Unexpected uterine smooth muscle tumor of uncertain malignant potential and sarcoma: A single center cohort study in South Korea

Anthony Kyung Woo Han et al.

TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY (2020)

Article Oncology

Multimodality adjuvant therapy and survival outcomes in stage I-IV uterine carcinosarcoma

Jennifer McEachron et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)

Editorial Material Obstetrics & Gynecology

Dose-dense chemotherapy: A possible high cost-effectiveness treatment for ovarian cancer

Chen-Yu Huang et al.

TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY (2020)

Article Environmental Sciences

Comparing Paclitaxel-Carboplatin with Paclitaxel-Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer

Chen-Yu Huang et al.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2020)

Article Obstetrics & Gynecology

Triple synchronous malignancies of the female genital tract with an advanced stage carcinosarcoma of the uterine cervix: A case report

Li-Chuan Hsu et al.

TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY (2020)

Article Oncology

State of the science: Uterine sarcomas: From pathology to practice

Alexander Shushkevich et al.

GYNECOLOGIC ONCOLOGY (2020)

Article Obstetrics & Gynecology

Predictive Histologic Factors in Carcinosarcomas of the Uterus: A Multi-institutional Study

Eman Abdulfatah et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2019)

Article Obstetrics & Gynecology

Primary peritoneal carcinosarcoma: A report of two cases

Hao-Sheng Fu et al.

TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY (2019)

Letter Obstetrics & Gynecology

Primary peritoneal carcinosarcoma (malignant mixed mullerian tumors)

Yueh-Han Hsu et al.

TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY (2019)

Review Radiology, Nuclear Medicine & Medical Imaging

Uterine carcinosarcoma: a primer for radiologists

Pavitra Ravishankar et al.

ABDOMINAL RADIOLOGY (2019)

Article Obstetrics & Gynecology

Paclitaxel-related dermatological problems: Not only alopecia occurs

Ming-Hsuan Su et al.

TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY (2019)

Review Obstetrics & Gynecology

Uterine sarcoma part III-Targeted therapy: The Taiwan Association of Gynecology (TAG) systematic review

Ming-Shyen Yen et al.

TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY (2016)

Review Obstetrics & Gynecology

Uterine sarcoma Part II-Uterine endometrial stromal sarcoma: The TAG systematic review

Huann-Cheng Horng et al.

TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY (2016)

Review Obstetrics & Gynecology

Uterine sarcoma Part I-Uterine leiomyosarcoma: The Topic Advisory Group systematic review

Kuo-Chang Wen et al.

TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY (2016)

Review Oncology

Uterine carcinosarcoma: A review of the literature

Leigh A. Cantrell et al.

GYNECOLOGIC ONCOLOGY (2015)

Article Oncology

Carboplatin-Paclitaxel Versus Cisplatin-Ifosfamide in the Treatment of Uterine Carcinosarcoma A Retrospective Cohort Study

Domenica Lorusso et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2014)

Review Oncology

Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine and Ovarian Carcinosarcoma

Dominique Berton-Rigaud et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2014)

Article Oncology

A Phase II Trial of Paclitaxel and Carboplatin in Women With Advanced or Recurrent Uterine Carcinosarcoma

Robin A. Lacour et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)

Article Medical Laboratory Technology

Pathologic and molecular features of uterine carcinosarcomas

Maria-Angeles Lopez-Garcia et al.

SEMINARS IN DIAGNOSTIC PATHOLOGY (2010)